ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA (NHL)

L.E Budde; A Vallurupalli; S Babu; I.S Lossos; J.P Alderuccio; J.C Chavez; H Eradat; H Holmes; M Hamadani; V.G Karur; A.J Olszewski; E Seymour; B Althaus; B.M Medeiros; C.C Li; A Kwan; M.C Wei; S Yin; C O'Hear; J Munoz

doi:10.1002/hon.12_2632

Back

ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA (NHL)

Journal article

Peer reviewed

ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA (NHL)

L.E Budde, A Vallurupalli, S Babu, I.S Lossos, J.P Alderuccio, J.C Chavez, H Eradat, H Holmes, M Hamadani, V.G Karur, …

Hematological oncology, Vol.37(S2), pp.564-566

2019-06

DOI: https://doi.org/10.1002/hon.12_2632

Metrics

14 Record Views

See more details

Details

Title: ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA (NHL)
Creators: L.E Budde - Department of Hematology & Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center; Duarte CA United States
A Vallurupalli - Division of Hematologic Malignancies and Cellular Therapeutics; University of Kansas Medical Center; Kansas City KS United States
S Babu - Fort Wayne Medical Oncology and Hematology; Fort Wayne; IN United States
I.S Lossos - Division of Hematology, Department of Medicine; Sylvester Comprehensive Cancer Center, University of Miami Health System; Miami FL United States
J.P Alderuccio - Division of Hematology, Department of Medicine; Sylvester Comprehensive Cancer Center, University of Miami Health System; Miami FL United States
J.C Chavez - Department of Malignant Hematology; Moffitt Cancer Center; Tampa FL United States
H Eradat - Division of Hematology-Oncology; David Geffen School of Medicine at UCLA; Los Angeles CA United States
H Holmes - Division of Medical Oncology - Hematology; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Dallas TX United States
M Hamadani - Division of Hematology & Oncology; Medical College of Wisconsin; Milwaukee WI United States
V.G Karur - Hematology and Oncology; Bayer Scott & White Clinic; Temple TX United States
A.J Olszewski - Department of Medicine; Warren Alpert Medical School of Brown University; Providence RI United States
E Seymour - Department of Oncology; Karmanos Cancer Institute/Wayne State University; Detroit MI United States
B Althaus - Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
B.M Medeiros - Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
C.C Li - Clinical Pharmacology, gRED; Genentech, Inc.; South San Francisco CA United States
A Kwan - Safety Science Oncology; Genentech, Inc.; South San Francisco CA United States
M.C Wei - Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
S Yin - Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
C O'Hear - Product Development Oncology; Genentech, Inc.; South San Francisco CA United States
J Munoz - Department of Hematology-Oncology; Banner MD Anderson Cancer Center; Gilbert AZ United States
Publication Details: Hematological oncology, Vol.37(S2), pp.564-566
Academic Unit: UMMG Dept of Medicine - Hematology/Oncology; Miller School of Medicine
Language: English
Resource Type: Journal article
Record Identifier: 991031599973902976